TEAM ACRAS DE MORUE

The Biologics Market is experiencing steady and robust growth, with its valuation set at USD 374.57 billion in 2024 and anticipated to reach USD 610.0 billion by 2035, reflecting a compound annual growth rate (CAGR) of 4.54% during 2025–2035. This growth is underpinned by rising demand for advanced therapeutic solutions, driven largely by the increasing global prevalence of chronic and life-threatening conditions such as cancer, autoimmune disorders, and rare genetic diseases.

Biologics — including monoclonal antibodies, vaccines, cell and gene therapies, recombinant proteins, and hormones — have revolutionized treatment approaches, offering highly targeted and effective interventions. North America currently dominates the market, with its strong healthcare infrastructure, high investment in R&D, and favorable regulatory environment, while Europe follows closely with supportive healthcare policies. Asia-Pacific is emerging as the fastest-growing region due to expanding healthcare access and local biologics manufacturing capabilities.